Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Lithium treatment in Alzheimer's disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects.

× No keyword cloud information.

7 in total

1. Lithium and dementia: a preliminary study.

Authors: Takeshi Terao; Hideki Nakano; Yoshiaki Inoue; Tatsuya Okamoto; Jun Nakamura; Noboru Iwata
Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2006-06-06 Impact factor: 5.067

2. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder.

Authors: Paula V Nunes; Orestes V Forlenza; Wagner F Gattaz
Journal: Br J Psychiatry Date: 2007-04 Impact factor: 9.319

3. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

Authors: Tobias Engel; Paloma Goñi-Oliver; José J Lucas; Jesús Avila; Félix Hernández
Journal: J Neurochem Date: 2006-10-24 Impact factor: 5.372

4. Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia.

Authors: S D Brinkman; N Pomara; N Barnett; R Block; E F Domino; S Gershon
Journal: Biol Psychiatry Date: 1984-02 Impact factor: 13.382

Review 5. Lithium and cognitive enhancement: leave it or take it?

Authors: Eleftheria Tsaltas; Dimitris Kontis; Vasileios Boulougouris; George N Papadimitriou
Journal: Psychopharmacology (Berl) Date: 2008-09-10 Impact factor: 4.530

6. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

Authors: Antonella Caccamo; Salvatore Oddo; Lana X Tran; Frank M LaFerla
Journal: Am J Pathol Date: 2007-05 Impact factor: 4.307

7. A feasibility and tolerability study of lithium in Alzheimer's disease.

Authors: Alastair Macdonald; Kate Briggs; Michaela Poppe; Andrea Higgins; Latha Velayudhan; Simon Lovestone
Journal: Int J Geriatr Psychiatry Date: 2008-07 Impact factor: 3.485

7 in total

6 in total

1. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Authors: Raquel Gómez-Sintes; José J Lucas
Journal: J Clin Invest Date: 2010-06-07 Impact factor: 14.808

Lithium treatment in Alzheimer's disease does not promote cognitive enhancement, but may exert long-term neuroprotective effects.

1. Lithium and dementia: a preliminary study.

2. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder.

3. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

4. Lithium-induced increases in red blood cell choline and memory performance in Alzheimer-type dementia.

Review 5. Lithium and cognitive enhancement: leave it or take it?

6. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

7. A feasibility and tolerability study of lithium in Alzheimer's disease.

1. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.

Review 2. Glycogen synthase kinase-3 as a therapeutic target for cognitive dysfunction in neuropsychiatric disorders.

Review 3. Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

Review 4. GSK-3β, a pivotal kinase in Alzheimer disease.

5. Lithium enhances survival and regrowth of spinal motoneurons after ventral root avulsion.

6. Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study.